MX2013000821A - Nuevas aminopirazoloquinazolinas. - Google Patents
Nuevas aminopirazoloquinazolinas.Info
- Publication number
- MX2013000821A MX2013000821A MX2013000821A MX2013000821A MX2013000821A MX 2013000821 A MX2013000821 A MX 2013000821A MX 2013000821 A MX2013000821 A MX 2013000821A MX 2013000821 A MX2013000821 A MX 2013000821A MX 2013000821 A MX2013000821 A MX 2013000821A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- aminopyrazoloquinazolines
- new
- compounds
- medicaments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención comprende compuestos de la fórmula general (I) (ver fórmula (I)) en donde los radicales R1 hasta R3 y X están definidos como en la reivindicación 1, que son apropiados para el tratamiento de enfermedades que se caracterizan por una proliferación celular excesiva o anómala, a preparaciones farmacéuticas que contienen tales compuestos y a su empleo como medicamentos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10170683 | 2010-07-23 | ||
PCT/EP2011/062683 WO2012010704A1 (en) | 2010-07-23 | 2011-07-22 | New aminopyrazoloquinazolines |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2013000821A true MX2013000821A (es) | 2013-05-30 |
Family
ID=43037625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013000821A MX2013000821A (es) | 2010-07-23 | 2011-07-22 | Nuevas aminopirazoloquinazolinas. |
Country Status (22)
Country | Link |
---|---|
US (1) | US8735386B2 (es) |
EP (1) | EP2595987B1 (es) |
JP (1) | JP5991974B2 (es) |
KR (1) | KR20130132394A (es) |
CN (1) | CN103097388A (es) |
AP (1) | AP2012006640A0 (es) |
AR (1) | AR082850A1 (es) |
AU (1) | AU2011281504A1 (es) |
BR (1) | BR112013000107A2 (es) |
CA (1) | CA2803467A1 (es) |
CL (1) | CL2012003745A1 (es) |
CO (1) | CO6670575A2 (es) |
EA (1) | EA201201661A1 (es) |
EC (1) | ECSP13012448A (es) |
GE (1) | GEP20156289B (es) |
MA (1) | MA34389B1 (es) |
MX (1) | MX2013000821A (es) |
PE (1) | PE20131143A1 (es) |
SG (1) | SG187548A1 (es) |
TW (1) | TW201217380A (es) |
UY (1) | UY33526A (es) |
WO (1) | WO2012010704A1 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9150578B2 (en) * | 2012-01-23 | 2015-10-06 | Boehringer Ingelheim International Gmbh | 5,8-dihydro-6H-pyrazolo[3,4-h]quinazolines as IGF-1R/IR inhibitors |
US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
KR20240006008A (ko) * | 2013-11-15 | 2024-01-12 | 온코슈틱스 인코포레이티드 | 7-벤질-4-(2-메틸벤질)-2,4,6,7,8,9-헥사하이드로이미다조[1,2-a]피리도[3,4-e]피리미딘-5(1H)-온,이의 염 및 이의 용도 |
PL3250208T3 (pl) | 2015-01-30 | 2021-04-06 | Oncoceutics, Inc. | 7-benzylo-4-(4-(trifluorometylo)benzylo)-1,2,6,7,8,9-heksahydroimidazo[1,2-a]pirydo[3,4-e]pirymidyn-5(4h)-on oraz jego sole i ich zastosowanie w terapii |
US10414769B2 (en) | 2015-05-13 | 2019-09-17 | Boehringer Ingelheim International Gmbh | 5,8-dimethyl-9-phenyl-5,8-dihydro-6H-pyrazolo[3,4-h]quinazolin-2-yl)-(1H-pyrazol-3-yl)-amines as IGF-1R/IR inhibitors |
CA3039012C (en) * | 2016-11-11 | 2021-08-24 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof |
CN108484600B (zh) * | 2017-05-26 | 2022-12-13 | 江苏新元素医药科技有限公司 | 促尿酸排泄的urat1抑制剂 |
CN107383019B (zh) * | 2017-07-28 | 2019-10-15 | 江苏艾凡生物医药有限公司 | 吡唑并[4,3-h]喹唑啉类化合物及其用途 |
EP3786161A4 (en) * | 2018-04-24 | 2021-05-05 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd | CDK4 / 6 INHIBITOR, PHARMACEUTICALLY ACCEPTABLE SALT, POLYMORPHIC OF THEM AND ASSOCIATED USE |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
EP3917514A4 (en) * | 2019-01-30 | 2023-02-22 | Yale University | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF FIBROSIS |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
CN113518775A (zh) * | 2019-03-07 | 2021-10-19 | 生物技术公司 | 用于制备经取代的咪唑并喹啉的方法 |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
CN113710225A (zh) * | 2019-04-19 | 2021-11-26 | 范德生物公司 | 活性剂在皮肤内的递送和保留 |
WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
JP2023509260A (ja) | 2019-08-14 | 2023-03-08 | インサイト・コーポレイション | Cdk2阻害剤としてのイミダゾリルピリミジニルアミン化合物 |
AR120184A1 (es) | 2019-10-11 | 2022-02-02 | Incyte Corp | Aminas bicíclicas como inhibidoras de la cdk2 |
CA3181162A1 (en) | 2020-06-05 | 2021-12-09 | Stephen W. Kaldor | Inhibitors of fibroblast growth factor receptor kinases |
CN111960974A (zh) * | 2020-08-28 | 2020-11-20 | 山东潍坊润丰化工股份有限公司 | 一种烯草酮中间体的合成方法 |
JP2024505714A (ja) * | 2021-02-08 | 2024-02-07 | メッドシャイン ディスカバリー インコーポレイテッド | 5,6-ジドヒロチエノ[3,4-h]キナゾリン系化合物 |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ98998A3 (cs) * | 1995-10-02 | 1998-10-14 | F. Hoffmann-La Roche Ag | Deriváty pyrimidinu jako antagonisty 5HT2C receptoru |
ME00142B (me) | 2003-05-22 | 2010-10-10 | Nerviano Medical Sciences Srl | Derivati pirazolo-hinazolina, postupci za njihovo dobijanje i njihova upotreba kao inhibitora kinaze |
CN1897950A (zh) * | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
-
2011
- 2011-07-20 US US13/187,100 patent/US8735386B2/en active Active
- 2011-07-21 UY UY0001033526A patent/UY33526A/es not_active Application Discontinuation
- 2011-07-22 BR BR112013000107A patent/BR112013000107A2/pt not_active IP Right Cessation
- 2011-07-22 AU AU2011281504A patent/AU2011281504A1/en not_active Abandoned
- 2011-07-22 GE GEAP201113008A patent/GEP20156289B/en unknown
- 2011-07-22 WO PCT/EP2011/062683 patent/WO2012010704A1/en active Application Filing
- 2011-07-22 EA EA201201661A patent/EA201201661A1/ru unknown
- 2011-07-22 AP AP2012006640A patent/AP2012006640A0/xx unknown
- 2011-07-22 CA CA2803467A patent/CA2803467A1/en not_active Abandoned
- 2011-07-22 MX MX2013000821A patent/MX2013000821A/es active IP Right Grant
- 2011-07-22 TW TW100126062A patent/TW201217380A/zh unknown
- 2011-07-22 EP EP11734158.6A patent/EP2595987B1/en active Active
- 2011-07-22 CN CN201180043930XA patent/CN103097388A/zh active Pending
- 2011-07-22 SG SG2013003645A patent/SG187548A1/en unknown
- 2011-07-22 MA MA35577A patent/MA34389B1/fr unknown
- 2011-07-22 PE PE2013000125A patent/PE20131143A1/es not_active Application Discontinuation
- 2011-07-22 JP JP2013520164A patent/JP5991974B2/ja active Active
- 2011-07-22 AR ARP110102670A patent/AR082850A1/es unknown
- 2011-07-22 KR KR1020137003430A patent/KR20130132394A/ko not_active Application Discontinuation
-
2012
- 2012-12-28 CL CL2012003745A patent/CL2012003745A1/es unknown
-
2013
- 2013-01-22 CO CO13011464A patent/CO6670575A2/es active IP Right Grant
- 2013-02-19 EC ECSP13012448 patent/ECSP13012448A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2012003745A1 (es) | 2013-05-31 |
AU2011281504A1 (en) | 2013-01-10 |
EA201201661A1 (ru) | 2013-07-30 |
MA34389B1 (fr) | 2013-07-03 |
EP2595987B1 (en) | 2018-04-18 |
US20120238542A1 (en) | 2012-09-20 |
JP5991974B2 (ja) | 2016-09-14 |
ECSP13012448A (es) | 2013-03-28 |
TW201217380A (en) | 2012-05-01 |
CN103097388A (zh) | 2013-05-08 |
US8735386B2 (en) | 2014-05-27 |
CO6670575A2 (es) | 2013-05-15 |
EP2595987A1 (en) | 2013-05-29 |
SG187548A1 (en) | 2013-03-28 |
AP2012006640A0 (en) | 2012-12-31 |
PE20131143A1 (es) | 2013-10-23 |
JP2013532652A (ja) | 2013-08-19 |
BR112013000107A2 (pt) | 2016-05-17 |
CA2803467A1 (en) | 2012-01-26 |
AR082850A1 (es) | 2013-01-16 |
WO2012010704A1 (en) | 2012-01-26 |
KR20130132394A (ko) | 2013-12-04 |
GEP20156289B (en) | 2015-05-25 |
UY33526A (es) | 2012-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013000821A (es) | Nuevas aminopirazoloquinazolinas. | |
PH12015501074A1 (en) | Triazolopyrazine | |
TN2012000369A1 (en) | 5-alkynyl-pyrimidines | |
MX2009013935A (es) | Compuestos quimicos. | |
MX2013008868A (es) | Nuevas azaindolifenil sulfonamidas como inhibidores de serina/treonina cinasa. | |
PH12015501385A1 (en) | Autotaxin inhibitors | |
PH12014502524B1 (en) | Carboxylic acid compounds | |
TN2011000259A1 (en) | Substituted pyrimidines for the treatment of diseases such as cancer | |
MX2013004491A (es) | Boronatos como inhibidores de arginasa. | |
WO2010007116A3 (en) | Pyridons as pdk1 inhibitors | |
PH12014501913A1 (en) | New 5-alkynyl pyridine | |
PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
MX2011012643A (es) | 2,4-diaminopiridinas para el tratamiento de enfermedades caracterizadas por la proliferacion celular excesiva o anormal. | |
MX2012013274A (es) | Novedosos derivados de la pirimidina. | |
MX2010009837A (es) | Tiazolil-dihidro-indazoles. | |
TN2011000531A1 (en) | 5- alkynyl - pyridines | |
IN2012DN06600A (es) | ||
TN2011000530A1 (en) | Thia-triaza-cyclopentazulenes as pi3-kinases inhibitors for the treatment of cancer | |
TN2013000012A1 (en) | New aminopyrazoloquinazolines | |
WO2012022796A3 (de) | Neue kombinationen | |
TN2011000610A1 (en) | 2,4-diaminopyrimidines for the treatment of diseases characterised b y excessive or abnormal cell proliferation | |
TN2011000049A1 (en) | 5-alkynyl-pyrimidines | |
TN2010000408A1 (en) | Thiazolyl-dihydro-indazoles | |
UA107920C2 (en) | Substituted pyrimidine for the treatment of diseases such as cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |